HomePress ReleasesMilliporeSigma Signs MoU with Lotte Biologics for Biologics Manufacturing

MilliporeSigma Signs MoU with Lotte Biologics for Biologics Manufacturing

  • MilliporeSigma named preferred supplier for Lotte’s new biologics business
  • Companies to collaborate on facility design, workforce training on process development and testing
  • MilliporeSigma to supply manufacturing hardware and consumables and technical support

Burlington, MA, June 29, 2022 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA. The MoU contemplates that MilliporeSigma will be a preferred supplier to provide Lotte with technical consulting, training and expertise, products, technologies, and manufacturing solutions.

“Novel modalities are changing the landscape of medicine and are expected to rapidly expand in the coming years to support development of customized, next-generation therapies, drugs, and vaccines,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck KGaA, Darmstadt, Germany. “This collaboration is just one example of our ongoing commitment to impact life and health with science.”

The Life Science business of Merck KGaA, Darmstadt, Germany has well over 30 years’ experience in process development and GMP manufacturing. The company has helped bring more than 280 biologics to market and has released more than 100 GMP drug substances since 2012 across a range of molecules and scales.

“We are delighted to announce our collaboration with MilliporeSigma. We believe such a relationship is a perfect fit for our mutual growth and business value and we look forward to strengthening and fostering this partnership not only in the U.S. but further on a global level to place both parties on the best path for consistent success,” said Richard Lee, CEO of Lotte Biologics.

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?